Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | MC3R | P41968 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6468479 | 0.87 | PIM2 (0.39) | CNR1ADORA3TSHRMC4RADRA1A | |
| SCHEMBL6470819 | 0.76 | CDK2 (0.35) | CNR1LMNAKDM4EMEN1KMT2A | |
| SCHEMBL6469271 | 0.72 | SIRT6 (0.41) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL6469123 | 0.71 | HCAR3 (0.46) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL7109264 | 0.70 | TSHR (0.56) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL5133216 | 0.69 | NNMT (0.41) | HCAR3KDM4EMEN1KMT2A | |
| SCHEMBL7573577 | 0.68 | ADORA3 (0.42) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL5042470 | 0.67 | HCAR3 (0.46) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL4864337 | 0.66 | GABRP (0.38) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL3743154 | 0.65 | ADORA3 (0.47) | ADORA3TSHRMC4RADRA1AMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | claimed |
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | APP, BACE1, SNCA | CNR1 958/4885ADORA3 92/4885TSHR 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.